Article references (36 references )

  1. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006; 20(8): 1163-9. Google Scholar

  2. United Nations Programme on HIV/AIDS. The Gap Report. Geneva: UNAIDS. 2014; 1-83. Google Scholar

  3. National AIDS Control Council. Kenya AIDS Response Progress Report Progress towards Zero. NACC, Ministry of Health, Government of Kenya. 2014; 37. Google Scholar

  4. Pádua CA, César CC, Bonolo PF, Acurcio FA, Guimarães, MD. High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Braz J Med Biol Res. 2006 Apr; 39(4): 495-505. PubMed | Google Scholar

  5. Braitstein P, Ayuo P, Mwangi A, Wools-Kaloustian K, Musick B, Siika A, & Kimaiyo, S. Sustainability of first-line antiretroviral regimens: findings from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr. 2010 Feb; 53(2): 254-9. PubMed | Google Scholar

  6. Woldemedhin B, Wabe NT. The Reason for regimen change among HIV/AIDS patients initiated on first-line Highly Active Antiretroviral Therapy in Southern Ethiopia. N Am J Med Sci. 2012 Jan; 4(1): 19-23. PubMed | Google Scholar

  7. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. WHO, Geneva, Switzerland. 2010. Google Scholar

  8. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007 Feb 1;44(3):447-52. PubMed | Google Scholar

  9. Orrell C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker L-G, Wood R. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007; 12(1): 83-8. PubMed | Google Scholar

  10. The Australian HIV Observational Database. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med. 2002 Jan; 3(1): 28-36. PubMed | Google Scholar

  11. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, Saag MS. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis. 2003 Sep 1; 37(5): 714-22. PubMed | Google Scholar

  12. Kwobah CM, Mwangi AW, Koech JK, Simiyu GN, Siika AM. Factors Associated with First-Line Antiretroviral Therapy Failure amongst HIV-Infected African Patients: A Case-Control Study. World Journal of AIDS. 2012; (2): 271-278. Google Scholar

  13. Inzaule S, Otieno J, Kalyango J, Nafisa, L, Kabugo C, Nalusiba J, Karamagi C. Incidence and predictors of first-line antiretroviral regimen modification in western Kenya. PLoS One. 2014 Apr 2; 9(4): e93106. PubMed | Google Scholar

  14. Anlay DZ, Alemayehu ZA, Dachew BA. The rate of initial highly active antiretroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow-up study. AIDS Res Ther. 2016 Feb 17;13:10. PubMed | Google Scholar

  15. World Health Organization. Physical status: the use and interpretation of anthropometry. WHO, Geneva, Switzerland. 1995. Google Scholar

  16. World Health Organization. HIV / AIDS Programme Antiretroviral Therapy for HIV infection in adults and adolescents: Recommendations for a public health approach 2006 revision important: Addendum to 2006 WHO guidelines on antiretroviral therapy for HIV infection. WHO, Geneva, Switzerland. 2006. PubMed | Google Scholar

  17. National AIDS and STIS Control Programme. Kenya national clinical manual for ART providers: a concise and practical guide to ART provision. Nascop, Ministry of Health, Government of Kenya. 2007; 1-70. Google Scholar

  18. van der Klauw MM, Goudsmit R, Halie MR, van’t Veer MB, Herings RM, Wilson JH, Stricker BH. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med. 1999 Feb 22; 159(4): 369-74. PubMed | Google Scholar

  19. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association. 1958; 53(282): pp 457. Google Scholar

  20. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Swiss HIV Cohort Study et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010 Jan 11; 170(1): 57-65. PubMed | Google Scholar

  21. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, ATHENA Study Group. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy: The ATHENA cohort. AIDS (London, England). 2002; 16(5): 737-45. Google Scholar

  22. Maggiolo F, Arici C, Airoldi M, Ripamonti D, Quinzan G, Gregis G, Ravasio V, Bombana E, Suter F. Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. J Antimicrob Chemother. 2007 Mar; 59(3): 569-72. PubMed | Google Scholar

  23. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks JT, Weidle PJ. Clinical toxicity of Highly Active Antiretroviral Therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2007 Apr 1; 44(4): 456-62. PubMed | Google Scholar

  24. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R. Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr. 2007 Jul 1; 45(3): 304-10. PubMed | Google Scholar

  25. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF et al. The initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005 Nov 1; 40(3): 336-43. PubMed | Google Scholar

  26. Pádua CA, César CC, Bonolo PF, Acurcio FA, Guimarães MD. Self-reported adverse reactions among patients initiating antiretroviral therapy in Brazil. Braz J Infect Dis. 2007 Feb; 11(1): 20-6. PubMed | Google Scholar

  27. Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P, Funk M, Kaufman JS, Van Rie A, Macphail P. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 1; 48(11): 1617-23. PubMed | Google Scholar

  28. Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE and al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr. 2010 May 1; 54(1): 63-70. PubMed | Google Scholar

  29. Boyle A, Sonecha S, Mandalia, S, Nelson M. An investigation into frequency and reasons why patients switch antiretroviral therapy and which antiretrovirals are commonly implicated in toxicity. J Int AIDS Soc. 2012; 15(6(Suppl 4)). Google Scholar

  30. Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16: 18794. PubMed | Google Scholar

  31. Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after the introduction of tenofovir. PLoS One. 2013 May 22; 8(5): e63596. PubMed | Google Scholar

  32. Castelnuovo B, Kiragga A, Kamya MR, Manabe Y. Stavudine toxicity in women is the main reason for a treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):59-63. PubMed | Google Scholar

  33. Evans D, Takuva S, Rassool M, Firnhaber C, Maskew M. Prevalence of peripheral neuropathy in antiretroviral therapy naive HIV-positive patients and the impact on treatment outcomes: a retrospective study from a large urban cohort in Johannesburg, South Africa. J Neurovirol. 2012 Jun; 18(3): 162-71. PubMed | Google Scholar

  34. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, Enejosa J. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials. 2007 May-Jun; 8(3): 164-72. PubMed | Google Scholar

  35. Bygrave H, Kranzer K, Hilderbrand K, Jouquet G, Goemaere E, Vlahakis N, Trivino L, Makakole L, Ford N. Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. PLoS One. 2011 Mar 2; 6(3): e17609. PubMed | Google Scholar

  36. Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, D’Avino A, Borghetti A, Cauda R, Di Giambenedetto S. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis. 2012 Nov 12; 12: 296. PubMed | Google Scholar